81 related articles for article (PubMed ID: 19142869)
1. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays.
Charpin C; Secq V; Giusiano S; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
Int J Cancer; 2009 May; 124(9):2124-34. PubMed ID: 19142869
[TBL] [Abstract][Full Text] [Related]
2. Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas.
Charpin C; Giusiano S; Secq V; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
Int J Oncol; 2009 Apr; 34(4):983-93. PubMed ID: 19287955
[TBL] [Abstract][Full Text] [Related]
3. [Early breast carcinoma profiling based on quantitative immunocytochemistry can help predict the risk of early distant metastasis].
Taranger-Charpin C; Giusiano S; Secq V; Djemli A; Andrac L; Lavaut MN; Allasia C; Garcia S
Bull Acad Natl Med; 2009 Dec; 193(9):2045-60; discussion 2060-1. PubMed ID: 20666017
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk.
Giusiano S; Secq V; Carcopino X; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Iovanna JL; Garcia S; Boubli L; Birnbaum D; Charpin C
Int J Oncol; 2010 Apr; 36(4):889-98. PubMed ID: 20198333
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays.
Charpin C; Garcia S; Bonnier P; Martini F; Andrac L; Horschowski N; Lavaut MN; Allasia C
J Pathol; 1998 Apr; 184(4):401-7. PubMed ID: 9664906
[TBL] [Abstract][Full Text] [Related]
6. Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome.
Charpin C; Giusiano S; Charfi S; Secq V; Carpentier S; Andrac L; Lavaut MN; Allasia C; Bonnier P; Garcia S
Br J Cancer; 2009 Jul; 101(1):48-54. PubMed ID: 19513067
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin quantitative immunocytochemical assays in breast carcinomas.
Charpin C; Garcia S; Bouvier C; Devictor B; Andrac L; Choux R; Lavaut M
J Pathol; 1997 Mar; 181(3):294-300. PubMed ID: 9155715
[TBL] [Abstract][Full Text] [Related]
8. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays.
Giusiano S; Cochet C; Filhol O; Duchemin-Pelletier E; Secq V; Bonnier P; Carcopino X; Boubli L; Birnbaum D; Garcia S; Iovanna J; Charpin C
Eur J Cancer; 2011 Mar; 47(5):792-801. PubMed ID: 21194925
[TBL] [Abstract][Full Text] [Related]
10. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype.
Garcia S; Dalès JP; Charafe-Jauffret E; Carpentier-Meunier S; Andrac-Meyer L; Jacquemier J; Andonian C; Lavaut MN; Allasia C; Bonnier P; Charpin C
Hum Pathol; 2007 Jun; 38(6):830-41. PubMed ID: 17316758
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma.
Vo TN; Mekata E; Umeda T; Abe H; Kawai Y; Mori T; Kubota Y; Shiomi H; Naka S; Shimizu T; Murata S; Yamamoto H; Ishida M; Tani T
Breast Cancer; 2015 Mar; 22(2):117-28. PubMed ID: 23575921
[TBL] [Abstract][Full Text] [Related]
12. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
13. RACK1: A superior independent predictor for poor clinical outcome in breast cancer.
Cao XX; Xu JD; Liu XL; Xu JW; Wang WJ; Li QQ; Chen Q; Xu ZD; Liu XP
Int J Cancer; 2010 Sep; 127(5):1172-9. PubMed ID: 20020495
[TBL] [Abstract][Full Text] [Related]
14. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
15. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
16. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
18. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
Wiseman SM; Makretsov N; Nielsen TO; Gilks B; Yorida E; Cheang M; Turbin D; Gelmon K; Huntsman DG
Cancer; 2005 May; 103(9):1770-7. PubMed ID: 15770691
[TBL] [Abstract][Full Text] [Related]
20. Validation of an immunohistochemical signature predictive of 8-year outcome for patients with breast carcinoma.
Charpin C; Tavassoli F; Secq V; Giusiano S; Villeret J; Garcia S; Birnbaum D; Bonnier P; Lavaut MN; Boubli L; Carcopino X; Iovanna J
Int J Cancer; 2012 Aug; 131(3):E236-43. PubMed ID: 22120430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
